FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022502406> ?p ?o ?g. }

• W2022502406 endingPage "200" @default.
• W2022502406 startingPage "191" @default.
• W2022502406 abstract "Surgical ovariectomy and orchiectomy, first proposed over a century ago, are effective in breast and prostate cancer therapy, respectively. Later, the discovery of steroid hormones and their nuclear receptors led to the concept that inhibition of steroid receptor function by an antagonist prevents tumour growth. While the first anti-hormones, cyproteroneacetate (CPA) and tamoxifen were found accidentally, deeper understanding of nuclear receptors as transcription factors enabled more rational, structure-activity based drug discovery. Results from a drug-finding program on pure anti-estrogens will be reported. These new steroidal anti-estrogens are highly active, pure ER-antagonists that lead to an efficient degradation of the estrogen receptor α (ERα) protein without any agonistic activity. Data obtained in preclinical tumour models in mice and rats showed a high potency in growth inhibition of ERα-positive breast cancer. In parallel, by comparing three independently generated anti-estrogen-resistant breast cancer cell lines, it was our intention to gain insight into the mechanisms of endocrine resistance which will allow to define new approaches for the treatment of endocrine-resistant breast cancer. Candidate proteins potentially involved in mechanisms of anti-estrogen-resistant growth of breast cancer cell lines were analyzed. ERα and progesterone receptor (PR) expressions were lost on the protein level in all three anti-estrogen-resistant cell lines, whereas binding of epidermal growth factor (EGF) and protein expression of epidermal growth factor receptor (EGFR) were increased. Loss of ERα expression may be linked to the acquisition of anti-estrogen resistance and enhanced expression of the EGFR and of members of the S100 family of Ca2+-binding proteins may contribute to the outgrowth of resistant cells. Furthermore, we describe the pharmacological development of a novel, highly potent progesterone receptor antagonist. In rat mammary tumour models, treatment with the PR antagonist completely suppressed the growth of established tumours and prevented the development of breast tumours. Advanced prostate cancer is effectively treated by androgen ablation. However, this therapy becomes inefficient although the androgen receptor (AR) is still functionally expressed. One novel strategy for the treatment of advanced prostate cancer could be the selective inhibition of AR protein expression by anti-sense oligonucleotides or small interfering RNA (siRNA) molecules. Down-regulation of the human AR caused significant inhibition of LNCaP prostate cancer growth in vivo. Taken together, many promising alternatives for endocrine therapy of breast and prostate cancer are arising." @default.
• W2022502406 created "2016-06-24" @default.
• W2022502406 creator A5002682008 @default.
• W2022502406 creator A5007299835 @default.
• W2022502406 date "2005-02-01" @default.
• W2022502406 modified "2023-09-26" @default.
• W2022502406 title "Steroidhormone receptors as targets for the therapy of breast and prostate cancer—recent advances, mechanisms of resistance, and new approaches" @default.
• W2022502406 cites W1740737174 @default.
• W2022502406 cites W1778936260 @default.
• W2022502406 cites W1798685462 @default.
• W2022502406 cites W1821858011 @default.
• W2022502406 cites W1973151387 @default.
• W2022502406 cites W1974577953 @default.
• W2022502406 cites W1982334342 @default.
• W2022502406 cites W1982427071 @default.
• W2022502406 cites W1987160391 @default.
• W2022502406 cites W1987652819 @default.
• W2022502406 cites W1988679331 @default.
• W2022502406 cites W1992067336 @default.
• W2022502406 cites W1993379260 @default.
• W2022502406 cites W1998086840 @default.
• W2022502406 cites W1999466810 @default.
• W2022502406 cites W1999805805 @default.
• W2022502406 cites W2003955264 @default.
• W2022502406 cites W2005595390 @default.
• W2022502406 cites W2006239014 @default.
• W2022502406 cites W2008498145 @default.
• W2022502406 cites W2008849274 @default.
• W2022502406 cites W2012666964 @default.
• W2022502406 cites W2012855221 @default.
• W2022502406 cites W2015629450 @default.
• W2022502406 cites W2022635468 @default.
• W2022502406 cites W2028202182 @default.
• W2022502406 cites W2030300262 @default.
• W2022502406 cites W2033281378 @default.
• W2022502406 cites W2035179289 @default.
• W2022502406 cites W2036638605 @default.
• W2022502406 cites W2039556898 @default.
• W2022502406 cites W2045389096 @default.
• W2022502406 cites W2045895711 @default.
• W2022502406 cites W2056299617 @default.
• W2022502406 cites W2063785409 @default.
• W2022502406 cites W2067173291 @default.
• W2022502406 cites W2073661944 @default.
• W2022502406 cites W2079113033 @default.
• W2022502406 cites W2082559087 @default.
• W2022502406 cites W2090157467 @default.
• W2022502406 cites W2093207006 @default.
• W2022502406 cites W2095873383 @default.
• W2022502406 cites W2101904881 @default.
• W2022502406 cites W2127689958 @default.
• W2022502406 cites W2137983743 @default.
• W2022502406 cites W2155916082 @default.
• W2022502406 cites W2161174332 @default.
• W2022502406 cites W2252316235 @default.
• W2022502406 cites W2325609367 @default.
• W2022502406 cites W2329432584 @default.
• W2022502406 cites W2792786100 @default.
• W2022502406 cites W2950599814 @default.
• W2022502406 cites W4230495402 @default.
• W2022502406 cites W4231282467 @default.
• W2022502406 cites W4246992986 @default.
• W2022502406 cites W96290679 @default.
• W2022502406 doi "https://doi.org/10.1016/j.jsbmb.2004.12.002" @default.
• W2022502406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15860262" @default.
• W2022502406 hasPublicationYear "2005" @default.
• W2022502406 type Work @default.
• W2022502406 sameAs 2022502406 @default.
• W2022502406 citedByCount "32" @default.
• W2022502406 countsByYear W20225024062013 @default.
• W2022502406 countsByYear W20225024062017 @default.
• W2022502406 countsByYear W20225024062018 @default.
• W2022502406 countsByYear W20225024062021 @default.
• W2022502406 countsByYear W20225024062022 @default.
• W2022502406 countsByYear W20225024062023 @default.
• W2022502406 crossrefType "journal-article" @default.
• W2022502406 hasAuthorship W2022502406A5002682008 @default.
• W2022502406 hasAuthorship W2022502406A5007299835 @default.
• W2022502406 hasConcept C104317684 @default.
• W2022502406 hasConcept C121608353 @default.
• W2022502406 hasConcept C126322002 @default.
• W2022502406 hasConcept C134018914 @default.
• W2022502406 hasConcept C170493617 @default.
• W2022502406 hasConcept C172313692 @default.
• W2022502406 hasConcept C2776362946 @default.
• W2022502406 hasConcept C2777164284 @default.
• W2022502406 hasConcept C2777176818 @default.
• W2022502406 hasConcept C2779438470 @default.
• W2022502406 hasConcept C2780192828 @default.
• W2022502406 hasConcept C502942594 @default.
• W2022502406 hasConcept C530470458 @default.
• W2022502406 hasConcept C55493867 @default.
• W2022502406 hasConcept C63932345 @default.
• W2022502406 hasConcept C71924100 @default.
• W2022502406 hasConcept C84606932 @default.
• W2022502406 hasConcept C86339819 @default.
• W2022502406 hasConcept C86803240 @default.
• W2022502406 hasConceptScore W2022502406C104317684 @default.

• next